

Annual Meeting of Stockholders: Business Update

23 May 2024

Release approved by Juan Carlos Aragón,
Chief Executive Officer and Executive Director
Vioneering Technologies Inc.
ASX:VTI



Legal Information



Summary

The material contained in this presentation is intended to be general background information about Visioneering Technologies, Inc. ("VTI", or "Visioneering") and its activities.

The information is provided in a summary form, does not purport to be complete and may include information derived from publicly available sources that have not been independently verified. Accordingly, this presentation should not be relied upon as advice for investors or potential investors. It should be read in conjunction with VTI's periodic and continuous disclosure announcements lodged with the Australian Securities Exchange ("ASX"), which are available at www.asx.com.au.

No representation or warranty is made as to the accuracy, completeness or reliability of the information.

No financial product advice

This presentation is for information purposes only and does not take into account the investment objectives, financial position or needs of any particular investor. Investors or potential investors should seek independent professional advice in respect of their specific investment objectives, financial situation and particular needs before making any investment decision. VTI is not licensed to provide financial product advice in respect of its securities or any other financial products.

Risks

An investment in VTI is subject to known and unknown risks, some of which are beyond the control of VTI and its directors. VTI does not guarantee any particular rate of return in relation to VTI securities or the performance of VTI.

Forward-looking statements

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based on management's current expectations and beliefs (being statements about matters that are not historical facts), including but not limited to, statements related to VTI's financial performance, business strategy and goals, plans and prospects, potential benefits of VTI's products and technology, product development, timing of international regulatory approvals, market size, commercial success, and future financial performance. VTI uses words such as 'will', 'may', 'expect', 'intend', 'seek', 'would', 'should', 'could', 'continue', 'plan', 'estimate', 'anticipate', 'believe', 'probability', 'risk', 'aim', or other similar words to identify forward-looking statements.

These forward-looking statements are subject to risks and uncertainties that are difficult to predict and are based on assumptions as to future events that may not prove accurate.

Given the current uncertainties regarding the on-going impact of the COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated. Actual results may differ materially from what is expressed in this presentation and investors are cautioned not to place undue reliance on the current trading outlook.

Past performance

Past performance, including the pro forma historical information in this presentation is given for illustrative purposes only and

should not be relied on (and is not) an indication of future performance including future security price information. Historical information in this presentation relating to VTI is information that has been released to the market. For further information, please see past announcements released to the ASX. Nothing contained in this presentation nor any information made available to investors or potential investors is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or future.

Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

CHES Depositary Interests

VTI's CHES Depositary Interests (CDIs) are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933, as amended, and in accordance with the procedures established pursuant to the provisions of a no-action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no-action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this presentation.

No offer

This presentation is for information purposes only and is not and should not be considered an offer or an invitation to acquire securities or any other financial products in any jurisdiction in which, or to any person to whom, it would be unlawful to make such an offer or invitation.

Each recipient of this presentation should make its own enquiries and investigations regarding all information included in this presentation including the assumptions, uncertainties and contingencies which may affect VTI's future operations and the values and the impact that future outcomes may have on VTI.

The information in this presentation is subject to change and unless required by law, VTI is under no obligation to update this presentation (including any forward-looking statements) or its contents for any matter arising or coming to VTI's notice after the date of this presentation.

None of VTI, its officers, directors, employees and agents, nor any other person makes any representation or warranty, express or implied, as to, or endorsement of, VTI, the accuracy or completeness of any information, statements or representations contained in this presentation and none of them accepts responsibility or liability for any errors or omissions in this presentation whatsoever.

This document may not be reproduced or published, in whole or in part, for any purpose without the prior written consent of VTI. The distribution of this presentation outside of Australia may be restricted by law and any such restrictions should be observed.

This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in Australia, the United States or any other jurisdiction.

What We Do: Correct and Protect Vision



Our flagship NaturalVue Multifocal, addresses two high-need and underserved global populations while partnering with ECP's to enhance the visual health of patients.

Myopia

Global TAM* - >500M people

- US and China are projected to represent over 3/4 of the market value
- Correlates to elevated life-time risk for several ocular diseases which may result in blindness



~\$2B total TAM projected to grow to ~\$17B by 2030

Presbyopia

\$1.8 B Global Contact Lens TAM*

- Affects nearly everyone over age 45-50 in every part of the world
- Up to 85% of patients have compromised vision with traditional multifocal contact lens designs¹



\$1.0B market value projected to grow to ~\$1.8B by 2030

• Total Addressable Market by 2030
• Myopia – ages 5-24; Presbyopia- 1. VTI data on file 2013. As reported by eye care practitioners.

PROTECT Randomized Clinical Trial

- Preliminary interim 1-year results released in October 2023 – treatment effects were consistent with those of the only treatment approved by the FDA for myopia progression control
- Full interim 1-year results released in January 2024
- 3rd party CRO performed Adjusted Outcomes analysis, including one on a Common Study Population that matched the population range of two other myopia progression control studies
- Adjusted Outcomes for the Common Study Population indicated that NaturalVue Multifocal was 89% effective in slowing the progression of myopia based on refractive error, and 58% effective based on the change in axial length, compared to the control group
- Adjusted Outcomes based on refractive error are ~50% better than the adjusted results for the only FDA approved myopia progression control contact lens

Global Expansion

- Recently signed supply and distribution agreements in Belgium, Vietnam, the Middle East, Greece and Cyprus, Spain and Portugal, Italy, and the Latin American Region
- In negotiations with distributors in China, the Netherlands, Germany, Austria, Switzerland, and the Republic of Korea

2023 Operating Results

- FY23 net revenue US\$8.7M, up 19% over FY22
- Shipments to US ECPs US\$8.2M, up 4% over FY22
- Gross margin 54.9%, up from 45.5% in FY22
- Net cash used in operating activities improved 40% over FY22 level

Working Capital

- Convertible Notes converted, leaving VTI debt-free
- Cash sufficient to finance operations through Q1 FY'25
- Plan to explore additional capital in FY24

Contact Us

Dr. Juan Carlos Aragón

Chief Executive Officer and Executive Director

Visioneering Technologies

jaragon@vtivision.com

www.vtvisioninvestors.com

VTI-IR-ASX94



NaturalVue® Daily Disposable Multifocal Soft Contact Lenses

